Bionano Announces Publication Of First Multi-Site Study To Analyze The Utility Of OGM In Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics (NASDAQ: BNGO) announced the publication of a multi-site study comparing optical genome mapping (OGM) to traditional cytogenetic methods for detecting structural variants in multiple myeloma. The study highlights OGM's potential advantages over existing methods like FISH, CMA, and KT, particularly in identifying complex gene rearrangements in plasma cell neoplasms.
July 23, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano Genomics' publication of a multi-site study on the utility of optical genome mapping (OGM) in multiple myeloma could boost investor confidence in the company's technology, potentially leading to a positive short-term impact on its stock price.
The publication of a multi-site study demonstrating the advantages of OGM over traditional methods in detecting structural variants in multiple myeloma is a significant milestone for Bionano Genomics. This could lead to increased adoption of their technology, enhancing revenue prospects and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100